ClinicalTrials.gg
CompletedNCT01206972Updated Jan 18, 2017

Dose-confirmatory Bridging Study in Total Knee Replacement

A Phase 3 interventional study of Rivaroxaban (BAY59-7939) and Rivaroxaban (BAY59-7939) in Venous Thromboembolism, sponsored by Bayer. Completed at 33 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.

Enrollment
29th of 61
302 · median 272
Started
2010
with 2 others
Phase 3
26 of 61
5 open now
Registered
12th of 61
by date
Lead sponsor
15 of 61
Bayer

Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 29th largest by enrollment, is one of 3 that started in 2010, is one of 26 in phase 3, and was the 12th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing rivaroxaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing elective total knee replacement (TKR) and to confirm the extrapolability of global data to Japanese patients by comparing with data from overseas phase III study (RECORD 3 - Study 11356) and phase II studies.

03

Conditions studied

  • Venous Thromboembolism

Keywords

  • venous thromboembolism
  • prevention
  • orthopaedic surgery
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 20 years or above
  • Patients undergoing elective TKR (the first replacement of the applicable knee joint)
  • Patients' written to participation after receiving detailed verbal and written information on any study specific procedures in advance

Exclusion criteria

Exclusion Criteria:

  • Planned, staged major orthopedic surgery within 3 months prior to elective TKR or during this study
  • History of active bleeding (e.g. intracranial bleeding, gastrointestinal bleeding*), or high bleeding risk

    *: within 3 months prior to elective TKR for gastrointestinal bleeding

  • Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk
  • Severe impaired renal function (CLCR calculated by formula: \<30 mL/min)
  • Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media)
  • Ongoing anticoagulant therapy (e.g. warfarin, heparins and Factor Xa inhibitors other than study medication) that cannot be stopped (in the opinion of the investigator/sub investigator)
  • Subjects for whom epidural catheters are expected to be left in for longer than 18 hours post-operatively
  • Planned intermittent pneumatic compression during treatment period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Rivaroxaban (BAY59-7939)

  • Experimental
    Arm 2

    Drug: Rivaroxaban (BAY59-7939)

  • Experimental
    Arm 3

    Drug: Rivaroxaban (BAY59-7939)

  • Active comparator
    Arm 4

    Drug: Enoxaparin

Interventions

06

What researchers measure

Primary outcomes

  1. A composite endpoint of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causes

    Time frame: up to Day 13 (±2 days)

  2. Treatment-emergent bleeding (major, non-major clinically relevant, other non-major)

    Time frame: from the first intake of study medication to no later than 2 days after the last intake of study drug

Secondary outcomes

  1. deep vein thrombosis (total, proximal, distal)

    Time frame: up to Day 13 (±2 days)

  2. symptomatic venous thromboembolism

    Time frame: up to Day 13 (±2 days)

  3. major venous thromboembolism (proximal deep vein thromboembolism, pulmonary embolism or venous thromboembolism-related death)

    Time frame: up to Day 13 (±2 days)

  4. symptomatic venous thromboembolism

    Time frame: within 30 days after stop of treatment with study drug

07

Study locations

33 sites
  • Nagoya, Aichi 455-8530, Japan
  • Matsudo, Chiba 271-8511, Japan
  • Matsuyama, Ehime 790-8524, Japan
  • Kawanuma, Fukushima 969-6593, Japan
  • Koriyama, Fukushima 963-8501, Japan
  • Asahikawa, Hokkaido 078-8237, Japan
  • Hakodate, Hokkaido 040-8611, Japan
  • Sapporo, Hokkaido 060-8648, Japan
  • Kakogawa, Hyogo 675-8545, Japan
  • Kobe, Hyogo 657-0068, Japan
  • Nishinomiya, Hyogo 663-8501, Japan
  • Tsukuba, Ibaraki 305-0854, Japan
  • Iida, Nagano 395-8505, Japan
  • Sasebo, Nagasaki 857-8575, Japan
  • Tomigusuku, Okinawa 901-0243, Japan
  • Hirakata, Osaka 573-8511, Japan
  • Izumisano, Osaka 598-8577, Japan
  • Izumi, Osaka 594-0071, Japan
  • Kishiwada, Osaka 596-8501, Japan
  • Kishiwada, Osaka 596-8522, Japan
  • Osakasayama, Osaka 589-8511, Japan
  • Sakai, Osaka 599-8271, Japan
  • Takatsuki, Osaka 569-1192, Japan
  • Adachi, Tokyo 121-0064, Japan
  • Nerima-ku, Tokyo 177-8521, Japan
  • Fukuoka, 813-0017, Japan
  • Fukuoka, 819-8551, Japan
  • Kyoto, 602-8026, Japan
  • Osaka, 530-0012, Japan
  • Osaka, 558-8558, Japan
  • Saga, 849-8501, Japan
  • Saitama, 336-8522, Japan
  • Toyama, 930-8550, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2010
First posted
Sep 22, 2010
Start
Oct 2010
Primary completionActual
May 2011
CompletionActual
Jun 2011
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01206972
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 22, 2010
Start date
Oct 2010
Primary completion
May 2011
Completion
Jun 2011
Last update
Jan 18, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion